Peripheral Artery Disease Diagnostics and Therapeutics Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is peripheral artery disease diagnostics and therapeutics market size?

USD 1020.1 million in 2026 and USD 2621.9 million by 2036 at a 9.9% CAGR.

The peripheral artery disease diagnostics and therapeutics market is expected to rise from USD 1,020.1 million in 2026 to USD 2,621.9 million by 2036, registering a 9.9% CAGR during the forecast period. Medical teams carefully classify the different ways peripheral artery disease appears in patients. Each specific presentation helps guide doctors toward the most effective testing and treatment strategies. In May 2024, American Heart Association guidance defined 4 distinct clinical subsets for lower-extremity peripheral artery disease. Such clear clinical groupings help direct diagnostic assessments toward an explicit medical or procedural decision.

Regional care priorities strongly influence how healthcare networks invest in their vascular services. Providers in the United States and Germany emphasize guideline records and treatment appropriateness during product evaluations. Programs in South Korea and Japan emphasize tertiary-center experience and procedure-specific outcomes. This circulatory condition continues to affect An extensive global patient population. In September 2025, Nature Reviews Disease Primers reported stating about 230 million people being affected worldwide. This extensive disease prevalence sustains long-term clinical demand across cardiovascular-risk reduction and ongoing follow-up care.

Summary of Peripheral Artery Disease Diagnostics and Therapeutics Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Peripheral artery disease product selection advances as vascular teams connect diagnostic certainty with cardiovascular-risk management and limb-preservation care. Program decisions reflect guideline alignment and documented disease severity across participating clinical departments. Primary care teams require objective testing for patients presenting with atypical symptoms or no leg pain. Vascular clinicians assess arterial obstruction prior to selecting medicine or revascularization. Hospital committees value products backed by disease-specific evidence and complete procedural records. Cardiovascular-risk management sustains continuing medicine use across symptomatic patient groups. Clinical education is anticipated to improve diagnostic consistency across provider networks.
Product and Segment View	Segment direction is led by diagnostics, followed by antiplatelet therapy and hospitals across established PAD care pathways. Specification review is expected to center on diagnostic accuracy and treatment suitability across clinical services. Diagnostics is predicted to garner 69.0% share in 2026, led by testing requirements preceding treatment selection. Antiplatelet therapy is anticipated to hold 43.2% share in 2026 due to cardiovascular-event prevention across symptomatic care. Hospitals are likely to secure 34.0% share in 2026, driven by multidisciplinary vascular services and intervention capacity.
Geography and Growth Outlook	Country movement differs through provider capacity and payment structures across vascular networks. Commercial progress reflects diagnostic access and procedure oversight across hospital systems. South Korea is expected to grow at 12.3% CAGR by 2036, backed by tertiary-center intervention capacity. United States is predicted to scale at 11.6% CAGR during forecast period, guided by extensive vascular-service access. Germany is anticipated to rise 10.9% CAGR from 2026 to 2036, helped by integrated angiology and vascular-surgery pathways.
Competitive View	Competition centers on diagnostic imaging and peripheral intervention across PAD treatment pathways. Commercial progress favors companies offering procedural evidence and dependable technical assistance across provider networks. Philips and Abbott Laboratories are expected to compete across vascular imaging and peripheral intervention technologies. Johnson & Johnson MedTech is projected to address calcified lesions due to intravascular lithotripsy systems. Medtronic plc is anticipated to receive review across peripheral intervention and thrombus-removal procedures.
Analyst Perspective	Peripheral artery disease management requires coordinated planning across vascular medicine and surgery. Company progress is expected to improve through disease-specific evidence and clinician education across participating services. Clinical leaders assess product utility through diagnostic accuracy and treatment performance across complete PAD pathways. Hospital teams value products preserving coordination across imaging and intervention services. Regional education improves confidence during expansion across clinical sites and newly trained groups. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is peripheral artery disease diagnostics and therapeutics market segmented?

The peripheral artery disease diagnostics and therapeutics industry is segmented by component, diagnostics, therapeutics, end user, and region.

The peripheral artery disease diagnostics and therapeutics market is segmented by component, diagnostics, therapeutics, end user, and region. Component coverage includes diagnostics and therapeutics across established vascular-care pathways. Diagnostics coverage includes ankle-brachial index and duplex ultrasound followed by CT angiography, MR angiography, and catheter angiography. Therapeutics coverage addresses antiplatelet therapy and anticoagulants with lipid-lowering therapy, endovascular intervention, and surgical revascularization. End-user coverage spans hospitals and cardiology clinics with vascular surgery centers and ambulatory surgical centers. Regional coverage includes North America and Europe together with East Asia and South Asia and Pacific. Latin America and Middle East and Africa complete geographic analysis across developing vascular-care systems.

Why does diagnostics shape component selection?

Dias and colleagues reported 15 studies covering 9,067 arteries in February 2025, comparing duplex ultrasound with arteriography. Clinical evidence places diagnostic assessment at care entry since treatment selection follows documented obstruction and symptom severity. Hemodynamic tests identify reduced perfusion and anatomical imaging defines lesion location for medicine or revascularization planning. Therapeutic products enter vascular pathways following confirmed diagnoses and explicit treatment objectives established by multidisciplinary teams.

• In 2026, diagnostics is set to represent 69.0% share, driven by testing requirements preceding treatment selection. Hospital teams compare vascular imaging systems and hemodynamic tests across complete PAD pathways.
• Therapeutics addresses medical and procedural needs following documented disease severity. Treatment planning considers ischemic exposure and lesion anatomy during clinical review.

How does ankle-brachial index shape diagnostic selection?

Ankle-brachial index begins diagnostic review through a pressure comparison between upper and lower limbs across suspected PAD cases. Pan, Wang, and Huang reported AUC 0.924 for a composite diagnostic model in June 2025. Abnormal readings direct clinicians toward cardiovascular ultrasound for flow assessment or angiography equipment for lesion mapping. Resulting evidence connects symptom evaluation with a defined referral and treatment decision across vascular services.

• Ankle-brachial index is anticipated to secure 31.6% share in 2026, led by prompt administration and low equipment intensity. Vascular teams examine pressure results prior to requesting advanced anatomical imaging.
• Duplex ultrasound and angiographic methods provide distinct assessments across suspected arterial obstruction. Lesion location and planned intervention guide diagnostic selection among participating services.

Why does antiplatelet therapy shape therapeutic demand?

Antiplatelet therapy addresses cardiovascular-event exposure across symptomatic PAD care and post-revascularization follow-up involving recurrent ischemic risk. Anticoagulants extend medical management for selected patients carrying additional thrombotic exposure and documented bleeding considerations. Lipid-lowering treatment addresses atherosclerotic progression as endovascular therapy devices restore perfusion across flow-limiting lesions. Shahid and colleagues reported 12 studies comparing dual and single antiplatelet therapy following lower-extremity revascularization in October 2025.

• Based on therapeutic, antiplatelet therapy is forecast to garner 43.2% share in 2026 due to routine cardiovascular-event prevention across symptomatic care. Clinical teams examine ischemic exposure and bleeding history prior to medicine selection.
• Endovascular intervention and surgical revascularization address lesions producing severe symptoms or limb threat. Anatomical complexity and clinical urgency direct treatment assignment across vascular services.

Why do hospitals lead end-user demand?

Hospitals combine vascular laboratories with angiography suites and operating rooms for complete peripheral artery disease management. Cardiology clinics and vascular surgery centers extend assessment across selected outpatient pathways serving referred patients. Shaikh and colleagues recorded safe same-day discharge in 92.8% of peripheral endovascular cases during December 2025. Recorded discharge performance connects patient selection with post-procedure monitoring and institutional capacity planning across established vascular services.

• By end-user, hospitals are projected to hold 34.0% share in 2026 owing to multidisciplinary vascular services and intervention capacity. Clinical committees evaluate products across diagnostic confirmation and follow-up protocols.
• Cardiology clinics and vascular surgery centers extend access across regional referral networks. Ambulatory surgical centers address suitable interventions based on patient stability and procedural requirements.

What are drivers, restraints, and opportunities in peripheral artery disease diagnostics and therapeutics market?

Screening needs and guideline-directed treatment encourage diagnostic and therapeutic evaluation. Procedure scrutiny and unequal clinical access delay routine use across selected provider settings.

• Driver: Vascular teams require objective disease identification among patients presenting with atypical symptoms or no leg pain. Earlier diagnosis enables cardiovascular-risk management and timely limb-preservation referral.
• Restraint: Reimbursement scrutiny and procedure-appropriateness review extend approval timelines for intervention technologies. Providers need defensible patient-selection records and complete clinical rationale for invasive treatment.
• Opportunity: Adjunct hemodynamic measurements improve assessment among patients affected by arterial calcification or unclear ABI findings. Expanded ultrasound assessment connects vascular laboratories with treatment and surveillance pathways.

Centers for Disease Control and Prevention reported up to 4 in 10 people with PAD experience no leg pain in May 2024. Limited symptom recognition increases objective-testing needs among older adults and people carrying diabetes or smoking exposure. Diagnostic pathways are projected to combine ABI screening with imaging assessment for uncertain presentations.

Capital and compliance exposure remain constraints for office-based peripheral vascular procedures. United States Department of Health and Human Services Office of Inspector General reported atherectomy represented 75% of office-based laboratory procedures in May 2026. Greater scrutiny favors technologies backed by transparent utilization criteria and complete clinical records.

Adjunct ultrasound measurements create an opportunity for patients affected by calcified vessels or uncertain pressure findings. Sommerset and colleagues reported AUC 0.79 for worst-case pedal acceleration time in March 2025. Clinical validation is anticipated to guide assessment across foot-level perfusion and limb-threat evaluation.

How are country CAGRs aligned in peripheral artery disease diagnostics and therapeutics market?

Country or Market	CAGR
South Korea	12.3%
United States	11.6%
Germany	10.9%
United Kingdom	10.4%
Japan	8.2%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in peripheral artery disease diagnostics and therapeutics market?

Country comparison shows a gradual step-down across profiled markets. South Korea occupies first position, followed by United States. Germany and United Kingdom form a closely grouped European tier. Japan completes comparison through established hospital-based vascular practice. A 4.1-point spread reflects different clinical capacity and payment conditions across profiled markets.

• South Korea leads comparison and establishes East Asia as first development cluster among markets shown.
• United States follows South Korea and maintains a limited gap from first position.
• Germany and United Kingdom form a comparable rate band through established vascular services.
• Japan completes disclosed comparison through nationwide endovascular experience and procedural monitoring.
• Profiled rates form a gradual downward slope instead of a sharp separation among national markets.

Markets carrying similar CAGRs present different entry conditions through provider concentration and payment structures. Full report coverage extends across North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Country-wise Analysis

• Peripheral artery disease diagnostics and therapeutics sector in South Korea is anticipated to rise at 12.3% CAGR between 2026 and 2036, reflecting concentrated tertiary vascular activity. Woo and colleagues examined 506 patients in a Korean multicenter registry published in May 2024, confirming structured evidence for claudication and chronic limb-threatening ischemia decisions. Registry-based case review gives manufacturers a clear framework for product comparison and adoption across high-volume vascular centers.
• American Heart Association News reported in May 2024 for 10 million to 12 million adults aged 40 years or older having PAD, indicating a broad testing and treatment population. Outpatient laboratories and hospital vascular teams convert this patient burden into recurring diagnostic assessment and revascularization activity. Sales in the United States are estimated to record 11.6% CAGR by 2036, aligned with extensive clinical access across multiple care settings.
• Integrated angiology and vascular-surgery pathways connect perfusion measurement with intervention planning, allowing suppliers to address procedure preparation and recovery monitoring within one system. Gerken and colleagues assessed 29 patients around lower-limb revascularization in July 2024, demonstrating how microvascular measurements document physiological changes after restored blood flow. Industry in Germany is projected to expand at 10.9% CAGR during the assessment period, backed by coordinated vascular departments apply evidence-led evaluation.
• Peripheral artery disease diagnostics and therapeutics market in the United Kingdom is forecast to increase at 10.4% CAGR from 2026 to 2036, driven by national audit coverage. Regional referral networks use audited procedure records to compare clinical performance and plan equipment or medicine requirements across vascular units. National Vascular Registry documented 16,618 lower-limb revascularization procedures during 2024 in its November 2025 report, showing substantial use of imaging and follow-up services.
• Nakahashi and colleagues analyzed 73,990 Japanese patients undergoing endovascular therapy in a registry published in February 2025, providing a large evidence base for bleeding-risk management. Demand in Japan is predicted to rise at 8.2% CAGR during the forecast period, helped by measured technology review across established hospital programs. Nationwide registry depth enables physicians to compare procedural outcomes and standardize post-intervention monitoring across participating vascular centers.

Who are notable companies in peripheral artery disease diagnostics and therapeutics market?

Philips, Abbott Laboratories, Johnson & Johnson MedTech, and Medtronic plc are the notable companies influencing this market.

Competition is anticipated to center on diagnostic precision and procedural performance. Hospital teams are likely to compare clinical evidence and education resources prior to product selection. Philips is expected to receive attention due to peripheral imaging and interpretation training. Abbott Laboratories is projected to address below-knee vessel treatment. Johnson & Johnson MedTech is estimated to address calcified peripheral lesions. Medtronic plc is anticipated to compete across revascularization and thrombus-removal procedures.

• Philips and Abbott Laboratories are expected to gain review attention based on vascular imaging and peripheral intervention portfolios. Clinical teams assess image interpretation and vessel treatment across complete PAD pathways.
• Johnson & Johnson MedTech is anticipated to compete depending on calcium-modification systems for difficult peripheral lesions. Vascular programs compare lesion crossing and plaque modification across heavily calcified targets.
• Medtronic plc is forecast to address peripheral intervention involving revascularization and thrombus removal. Clinical teams examine aspiration performance and anatomical reach across complex arterial obstruction.

Competitive Benchmarking: Peripheral Artery Disease Diagnostics and Therapeutics Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
Philips	High	High	High	United States and selected global markets
Abbott Laboratories	High	High	High	United States and selected global markets
Johnson & Johnson MedTech	High	High	High	United States and selected global markets
Medtronic plc	High	High	High	United States and selected global markets

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Peripheral Artery Disease Diagnostics and Therapeutics Market

• In March 2025, Johnson & Johnson MedTech announced United States launch of Shockwave Javelin Peripheral IVL Catheter for difficult-to-cross calcified lesions. Forward lithotripsy expands calcium modification across severely narrowed peripheral vessels.
• In August 2025, Abbott Laboratories announced European CE Mark for Esprit BTK Everolimus Eluting Resorbable Scaffold System. Drug delivery and scaffold resorption expand below-knee treatment options across limb-preservation services.
• In December 2025, Medtronic plc announced first commercial use of Liberant thrombectomy system. Mechanical aspiration expands catheter-based removal of fresh peripheral arterial or venous thrombi.

Key Players in Peripheral Artery Disease Diagnostics and Therapeutics Market

Vascular imaging and diagnostic company

• Philips

Peripheral therapeutic and intervention companies

• Abbott Laboratories
• Johnson & Johnson MedTech
• Medtronic plc

Peripheral Artery Disease Diagnostics and Therapeutics Market Report Scope

Coverage field	Report scope
Market breakdown	Peripheral Artery Disease Diagnostics and Therapeutics Market breakdown by component, diagnostics, therapeutics, end user, and region
Market Definition	Peripheral artery disease diagnostics and therapeutics include testing systems, medicines, devices, and clinical services for disease identification, cardiovascular-risk reduction, limb preservation, and arterial revascularization.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	South Korea, United States, Germany, United Kingdom, and Japan, with additional countries included across regional analysis.
Key Companies Profiled	Philips, Abbott Laboratories, Johnson & Johnson MedTech, and Medtronic plc
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment share and country CAGR with diagnostic activity, procedure participation, clinical evidence, and company coverage

Source: Future Market Insights analysis, 2026.

Peripheral Artery Disease Diagnostics and Therapeutics Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Peripheral Artery Disease Diagnostics and Therapeutics Market by Segments

Peripheral Artery Disease Diagnostics and Therapeutics Market segmented by Component:

• Diagnostics
• Therapeutics

Peripheral Artery Disease Diagnostics and Therapeutics Market segmented by Diagnostics:

• Ankle-Brachial Index
• Duplex Ultrasound
• CT Angiography
• MR Angiography
• Catheter Angiography

Peripheral Artery Disease Diagnostics and Therapeutics Market segmented by Therapeutics:

• Antiplatelet Therapy
• Anticoagulants
• Lipid-Lowering Therapy
• Endovascular Intervention
• Surgical Revascularization

Peripheral Artery Disease Diagnostics and Therapeutics Market segmented by End User:

• Hospitals
• Cardiology Clinics
• Vascular Surgery Centers
• Ambulatory Surgical Centers

Peripheral Artery Disease Diagnostics and Therapeutics Market segmented by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• American Heart Association. (2024, May 14). 2024 guideline for the management of lower extremity peripheral artery disease: Top things to know.
• Aboyans, V., Canonico, M. E., Chastaingt, L., Anand, S. S., Brodmann, M., Couffinhal, T., Criqui, M. H., Debus, E. S., Mazzolai, L., McDermott, M. M., & Bonaca, M. P. (2025, September 18). Peripheral artery disease. Nature Reviews Disease Primers, 11, Article 68.
• Dias, S. V. M., Flumignan, R. L. G., Carvas, N., & Iared, W. (2025, February 14). Accuracy of duplex ultrasound in peripheral artery disease: A systematic review and meta-analysis. Jornal Vascular Brasileiro, 24, e20240033.
• Pan, X., Wang, N., & Huang, Y. (2025, June 12). A multicenter study on the diagnostic value of ankle brachial index combined with pulse volume wave parameters for peripheral arterial disease. Frontiers in Cardiovascular Medicine, 12, 1580971.
• Shahid, M. M., Mandal, D., Das, A., Kumar, P., Kumar, N., Mukhtar, A., Ejaz, H., Jaffar, M. S., Habib, M., Afzal, A., Khawar, M. M. H., & Rana, I. (2025, October 26). Dual versus single antiplatelet therapy following lower extremity revascularization in peripheral artery disease: A systematic review and meta-analysis. World Journal of Cardiology, 17(10), 111941.
• Shaikh, F. M., Cliffe, H., O’Mahony, C., Swali, A., & Papp, L. (2025, December 19). Same-day discharge following endovascular peripheral interventions. International Angiology, 44(6), 497-502.
• Centers for Disease Control and Prevention. (2024, May 15). About peripheral arterial disease (PAD).
• United States Department of Health and Human Services, Office of Inspector General. (2026, May 4). Utilization trends and Medicare Part B billing for office-based peripheral vascular procedures raise questions about program integrity.
• Sommerset, J., Teso, D., Mills, J. L., Sr., Sebastian, M., Kayssi, A., Leask, S., Rounsley, R., & Tehan, P. E. (2025, March 13). Diagnostic test accuracy of pedal acceleration time to identify peripheral artery disease. European Journal of Vascular and Endovascular Surgery, 69(6), 876-886.
• Woo, H. Y., Joh, J. H., Kang, J. M., Yoo, Y. S., Lee, T., Ahn, S., & Korean Society for Vascular Surgery Investigators. (2024, May 30). Comparison between intermittent claudication versus chronic limb-threatening ischemia in peripheral arterial disease: A retrospective multicenter cohort study. Annals of Surgical Treatment and Research, 106(6), 344-353.
• American Heart Association News. (2024, May 14). New roadmap to lower the risk of amputation in peripheral artery disease.
• Gerken, A. L. H., Sigl, M., Israel, E., Weiss, C., Reissfelder, C., & Schwenke, K. (2024, July 8). The effect of revascularization on lower limb circulation parameters in symptomatic peripheral arterial disease. Journal of Clinical Medicine, 13(13), 3991.
• National Vascular Registry. (2025, November). 2025 NVR State of the Nation Report. Royal College of Surgeons of England.
• Nakahashi, T., Takahara, M., Iida, O., Kohsaka, S., Soga, Y., Horie, K., Sakata, K., Takamura, M., Amano, T., & Kozuma, K. (2025, February 24). Cumulative impact of procedural and anatomical factors on in-hospital bleeding complications in endovascular therapy for lower-extremity artery disease: A nationwide registry study in Japan. Vascular Medicine, 30(2), 155-161.
• Johnson & Johnson MedTech. (2025, March 4). Shockwave Medical launches novel forward intravascular lithotripsy platform in U.S. to transform treatment of difficult-to-cross calcified lesions.
• Abbott Laboratories. (2025, August 25). Abbott’s dissolving stent receives CE Mark, pioneering a new era in peripheral vascular treatment.
• Medtronic plc. (2025, December 10). Medtronic announces successful early commercial use of Liberant thrombectomy system.
• Philips. (2026, March 3). Arterial IVUS Tutor app launched in the US to support IVUS training.

This bibliography is provided for reader reference and is not exhaustive. The full report contains complete reference list and detailed citations.

This Report Answers

• What segments influence sales across component and diagnostics with therapeutics and end user?
• How do vascular teams evaluate peripheral artery disease diagnostics prior to routine clinical use?
• How do country CAGRs differ across profiled markets with distinct provider capacity and payment structures?
• What companies compete through diagnostic imaging and peripheral intervention across vascular-care networks?
• How are forecasts validated through hybrid bottom-up and top-down analysis using independent indicators?
• What evidence do hospital committees examine prior to multisite product expansion across vascular services?
• How do diagnostic accuracy and lesion assessment influence treatment selection across PAD pathways?
• What limits return on investment for providers adding peripheral vascular technologies across clinical services?
• How do education records and clinical guidance influence hospital approval across multidisciplinary vascular teams?
• What company capabilities improve long-term clinical confidence and continuing product utilization across provider networks?